News

Altogen Labs offers xenograft services for drug development of anti-cancer therapeutics

Altogen Labs offers xenograft services for drug development of anti-cancer therapeutics pdf

by Altogen Labs, 11200 Manchaca Rd, Suite 203 Austin TX 78744  info@altogenlabs.com

Introduction

Xenograft studies fuels the development of new therapeutics efficiently and effectively and remains the gold standard for preclinical oncology research [1]. Xenograft studies, over in vitro studies, provide a more accurate schema of both the development of a particular tumor as well as the efficacy of a drug [2]. In the preclinical phase of the development of new anti-cancer drugs and therapeutics, mouse models have been crucial to determining in vivo results for decades. Profiling a therapeutic agent can be accomplished through selecting an appropriate model, carrying out studies in different tumor types and evaluating efficacy with hematology analysis, histopathology, biomarker screening and pharmacokinetic analysis.

Xenograft services rely on use of immunocompromised small animals (laboratory mice and rats). Severe combined immune deficient (SCID) mice and nude mice are effective as proxies for human subjects.

scid

Figure 1. Xenograft and Anti-Cancer Therapeutics.

Image represents the basic design study for xenograft studies

Xenograft studies developed to research anti-cancer therapeutics must be rooted in technical skills such as surgical skills, general experience with drug development, thorough and efficient protocols, and most importantly, an extensive knowledge of tumors and immune-oncology. Anti-cancer therapeutic studies can investigate biomarker changes, drug efficacy, host longevity, metastases decline, delay in tumor growth and remission of tumor. Altogen Labs scientists possess years of experience and can assist with customizing the services in order to assist with designing the study and selecting the best model.

 

Research Study: Tumor Growth Delay in Mouse PANC-1 Xenograft Model

The goal of this study was to evaluate different test articles for efficacy against PANC-1 with the xenograft model.

Materials and methods:

Pancreas carcinoma PANC1 (CRL-1469) cell line was obtained from ATCC and cultured in ATCC-formulated Dulbecco’s Modified Eagle’s Medium (cat#302002), supplemented with fetal bovine serum to a final concentration of 10% (ATCC). Sub culturing was performed by cell trypsinization with 0.25% Trypsin-EDTA (2-3 minutes) and 1:4 split for every subsequent passage. Cell line was cultured at 37°C / 5% CO2 in humidified incubator.

Xenotransplantation (mouse xenograft model):

Immunocompromised nude mice (9- to 11-week old females) were purchased from the Harlan laboratories. All animal procedures and maintenance were conducted in accordance with the institutional guidelines. Cells were mixed (1:1 volume) with Matrigel (BD Biosciences) and cell line suspension (50% matrigel) was subcutaneously injected (1.0 x 106 cells per injection) in animal flank area to ensure successful tumor initiation and tumor growth measurements. Injection performed at respective day 0. Intravenous administration of compound (or control) started on day 7 after inoculation when measurable tumor growth was detected. Measurements of tumor volume (mm3) were performed by digital calipers every 4 days during 40 days after tumor inoculation.

Group # Mice Test Article* Total volume Route Dose Injection Times
1 10 F No Injection n/a n/a n/a n/a
2 10 F Vehicle 200ul IV 50 ug Days 0, 7, 11, 14
3 10 F Test Article 1 200ul IV 5 ug
4 10 F Test Article 1 200ul IV 50 ug
5 10 F Test Article 2 200ul IV 5 ug
6 10 F Test Article 2 200ul IV 50 ug

Table 1. Standard study design to test different test articles for efficacy against PANC-1

Animals:          Athymic Nu/Nu mice

Xenograft:       PANC1 (CRL-1469) cells – subcutaneous implant (flank area)

Treatment started when average tumor reached 100-150 mm3

Endpoint:        Sacrifice animals when each tumor reaches 2,000 mm3 or Day 30 of the study

Services include: Gross necropsy, tumor size measurements (bi-weekly), report with statistical analysis

Results:

panc1xenograft

Figure 2. The capacity of Test Article 1 (TA1) and Test Article 2 (TA2) administered on Days 7, 11, 14 after tumor inoculation, was evaluated in subcutaneous PANC1 xenografts during 35 days after tumor inoculation (Day 0). Each group n=10.

Group 1 = No Injection

Group 2 = Vehicle

Group 3 = TA 1, 10 ug

Group 4 = TA 1, 50 ug

Group 5 = TA 2, 10 ug

Group 6 = TA 2, 50 ug

Conclusion

Transplanting tissue from one species to another species is truly a powerful tool; however, designing anti-cancer therapeutic studies involving xenografts also involves technical skill and experience. Altogen Labs has the knowledge, experience, and technical skills required for implementing this powerful research tool. Altogen Labs scientists can perform orthotopic, intramuscular, intravenous, intratracheal, or intraperitoneal administration.

To learn more about the extensive xenograft services that Altogen Labs offers, visit the Altogen Labs website: www.altogenlabs.com/pre-clinical-research-services/xenograft-animal-service-immunocompromised-nodscid-mice/

Altogen Labs offers a plethora of customizable preclinical biology services as well. Visit our website at:  www.altogenlabs.com

References:

  1. Ramos, P. and M. Bentires-Alj, Mechanism-based cancer therapy: resistance to therapy, therapy for resistance. Oncogene, 2015. 34(28): p. 3617-26.
  2. Scott, C.L., H.J. Mackay, and P. Haluska, Jr., Patient-derived xenograft models in gynecologic malignancies. Am Soc Clin Oncol Educ Book, 2014: p. e258-66.

Altogen Labs offers in vivo imaging services for drug development and biodistribution studies: Orthotopic glioma xenograft model

Altogen Labs offers in vivo imaging services for drug development and biodistribution studies: Example of orthotopic glioma xenograft animal model  by Altogen Labs, 11200 Manchaca Rd, Suite 203 Austin TX 78748 USA  Introduction In Vivo imaging has emerged as a critical tool in visualization in preclinical research studies related to the development of new therapeutic… Continue Reading

Biology CRO Contract Research Services to Accelerate Preclinical and Oncology Research Studies

Altogen Labs, a CRO laboratory located in Austin, Texas (USA), provides preclinical pharmacology and oncology contract research services for pharmaceutical, biotechnology, and academic research institutions worldwide. Company scientists bring years of experience and expertise in life science and drug discovery research services. Altogen Labs offers GLP-compliant research and development services that include preclinical trials to… Continue Reading

Altogen Labs Offers Pre-Clinical CRO Services to Accelerate Pre-Clinical Research Needs

Altogen Labs, a biotechnology company focused on providing biotechnology research services for pharmaceutical, biotechnology, and academic institutions worldwide, announced pre-clinical contract research services enabling companies to accelerate pre-clinical research needs. Pre-clinical trials assess the toxicity and pharmacological activity of investigative new drugs (INDs) to assess a compound’s therapeutic potential and safety for human use. A… Continue Reading

Comparison of Commercial Transfection Reagents: Cell line optimized transfection kits for cancer research studies

Comparison of Commercial Transfection Reagents: Cell line optimized transfection kits for in vitro cancer research. by Altogen Labs, 11200 Manchaca Road, Suite 203 Austin TX 78748 USA Tel. (512) 433-6177 E-mail: info@altogenlabs.com  Website: www.altogenlabs.com Introduction The process of in vitro transfection involves introduction of genetic material into cells and it is generally used for mammalian… Continue Reading

Altogen Labs Launches In Vivo siRNA Liposome Encapsulation Services

Altogen Labs has announced the release of a new contract research services (CRO) product: small interfering RNA (siRNA) liposome encapsulation, a technique used in biology laboratories to enable in vivo delivery of siRNA. Liposome encapsulation platform uses latest microfluidizer (Microfluidics) technology and is unique in its ability to achieve liposomal protection of functional siRNA molecules, provide… Continue Reading

PEG-Liposome siRNA In Vivo Transfection Kit From Altogen

Altogen announced the release of its second generation of in vivo RNAi transfection reagent in the company’s popular in vivo delivery product line: PEG-Liposome siRNA In Vivo Transfection Kit. This reagent is compatible for in vivo transfection of other negatively charged molecules – RNA, DNA, and small proteins. The company also offers custom encapsulation of target molecules Read Continue Reading

Altogen Labs Announces Patent Filing for Bioremediation Process and Oil Spill Cleanup Products

Altogen Labs announced the filing of a patent for bioremediation microorganism isolation and selection methods (USPTO application 13/490,508). This environmental technology is based on isolation of naturally present microorganisms in heavily contaminated soil, which allows accelerating natural bioremediation processes. We don’t have to wait hundreds of years for nature to degrade an oil spill or… Continue Reading

Texas-Based Biotechnology Company Develops Oil-Degrading Bacteria

Altogen Labs announced that it has successfully isolated natural oil-eating bacteria from polluted soil near Galveston Bay, Texas that has been shown in laboratory tests to be effective for the bioremediation of crude oil and petroleum saturated earth. Bioremediation is a process involving microorganisms, fungi, green plants, or their enzymes to restore the natural environment to… Continue Reading